You are here

  • Home
  • Archive
  • Volume 16, Issue 3
  • Combined prophylactic β-blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy alone, or optimised acute treatment only

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Combined prophylactic β-blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy alone, or optimised acute treatment only

https://doi.org/10.1136/ebm1177

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests RBL has received research grants, lecture honoraria or consulting fees from several manufacturers of migraine medications such as Allergan, Inc, Bristol Meyers Squibb, Johnson and Johnson, the National Institutes of Health, the National Headache Foundation, Glaxo SmilthKline, Pfizer, Inc, Merck, MAP, Nautilus Neurosciences and Novartis.